Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, United Kingdom
Serc-8.
| Pharmaceutical Form |
|---|
|
A round, flat, white to almost white tablet. Serc-8 is imprinted ‘256’ on one face of the tablet. |
Each tablet contains 8 mg betahistine dihydrochloride equivalent to 5.21 mg betahistine.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Betahistine |
Betahistine dihydrochloride is a histamine-like drug in which pharmacological activity can be attributed to a specific effects and/or more direct influences on recovery mechanisms the vestibular nuclei. It has weak agonist activity at histamine H1 receptors and moderate antagonist activity at H3 receptors. Betahistine may increase blood flow to the cochlear region as well as to the whole brain. |
| List of Excipients |
|---|
|
Microcrystalline cellulose |
Blister strips of 30 tablets. The blister strips are made of PVC/PVdC film and aluminium foil. Each carton contains 120 tablets.
Grey polypropylene tablet container with white polypropylene tamper evident closure containing 500 or 1000 tablets.
Not all pack sizes may be marketed.
Mylan Products Ltd., 20 Station Close, Potters Bar, Herts, EN6 1TL, United Kingdom
PL 46302/0049
7 October 98
| Drug | Countries | |
|---|---|---|
| SERC | Austria, Canada, Spain, France, Ireland, Mexico, New Zealand, Tunisia, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
